A Phase 1/2 interventional study of Nanoparticle Paclitaxel in Coronary Restenosis, sponsored by Celgene Corporation. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-02.
Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following de novo stenting or following angioplasty for in-stent restenosis.
This study consisted of a Phase I non-randomized dose escalation phase to determine the maximum tolerated dose and a randomized Phase II component to assess preliminary efficacy. Nanoparticle paclitaxel was administered by intracoronary catheter following either successful and uncomplicated stenting of de novo lesions in native coronary arteries or following successful and uncomplicated balloon angioplasty of instent restenosis (ISR) lesions.
107 studies on the registry are indexed under Coronary Restenosis; 10 are open to participants now.
This study's enrollment of 112 is below the median of 242 across 69 interventional studies indexed under Coronary Restenosis.
Browse Coronary Restenosis studies →Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.
First submitted before Celgene became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following lab values at baseline are exclusionary:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of 10 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesion) or balloon angioplasty (in-stent restenosis lesions).
Drug: Nanoparticle Paclitaxel
Participants received a single dose of 22 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
Drug: Nanoparticle Paclitaxel
Participants received a single dose of 35 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
Drug: Nanoparticle Paclitaxel
Participants received a single dose of 45 mg/m\^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
Drug: Nanoparticle Paclitaxel
Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
Also known as: ABI-007, Abraxane®, Coroxane™
Phase I: Number of Participants With Dose-limiting Toxicities
Toxicities were evaluated based on the U.S. National Cancer Institute (NCI) Common Terminology Criteria (CTC) for Adverse Events version 3.0. Any drug-related toxicities considered CTC Grade 3 or 4 were considered dose limiting. The maximum tolerated dose was defined as the lesser of 45 mg/m\^2 or the dose at which any drug related toxicities were observed.
Time frame: Up to 1 week following percutaneous coronary intervention.
Number of Participants With Procedural Complications
Procedural complications include the following: 1. Haemodynamic monitoring: changes in heart rate, arterial blood pressure or electrocardiogram changes; 2. Arrhythmia: premature ventricular complexes, brady or tachyarrhythmia; 3. Allergic reactions: rash, flushing, pyrexia, urticaria, angio-oedema; 4. Angiographic complications: coronary artery spasm, dissection, thrombosis, TIMI (Thrombolysis In Myocardial Infarction) flow, no reflow; 5. Clinical changes: chest pain.
Time frame: From Day 0 - Day 1 (from study drug administration until 24 hours post-procedure).
Number of Participants With Treatment Emergent Adverse Events (AEs)
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. An SAE is any event that: * is fatal or life threatening * results in persistent or significant disability or or incapacity; * requires or prolongs existing hospitalization; * is a congenital anomaly/birth defect in the offspring of a patient who received medication; * conditions not included above that may jeopardize the patient or require intervention to prevent one of the outcomes listed above.
Time frame: Up to 6 months.
Number of Participants With Major Adverse Cardiac Events (MACE) at 1 Month
Major Adverse Cardiac Events (MACE) includes cardiac death, Coronary Artery Bypass Surgery, Myocardial Infarction, Target Vessel Revascularization (TVR) or Target Lesion Revascularization (TLR) and stent/vessel thrombotic occlusion.
Time frame: From the day of Percutaneous Coronary Intervention to 1 Month.
Number of Participants With Major Adverse Cardiac Events (MACE) at 6 Months
Major Adverse Cardiac Events (MACE) includes cardiac death, Coronary Artery Bypass Surgery, Myocardial Infarction, Target Vessel Revascularization (TVR) or Target Lesion Revascularization (TLR) and stent/vessel thrombotic occlusion.
Time frame: From the day of Percutaneous Coronary Intervention to Month 6.
Percentage of Participants With Binary Restenosis
Binary restenosis was assessed by quantitative coronary angiography and defined as \>50% diameter stenosis within the stented region (In-stent) or the stented region plus 5 mm on either side of the stent (In-segment) at follow-up. Angiograms were centrally assessed by the Angiographic Core Laboratory.
Time frame: 6 months
Late Lumen Loss
Late lumen loss represents the extent of neointimal hyperplasia within the stented region (In-stent) or the stented region plus 5 mm on either side of the stent (In-segment) and was measured by quantitative coronary angiography. Late Loss = Minimum Lumen Diameter (MLD) Post Procedure minus the MLD at Follow-up.
Time frame: Day 0 (post-procedure baseline) and 6 months.
Percentage of In-Stent Volume Obstruction at 6 Months
In-stent volume obstruction at 6 months was measured by intra-vascular ultrasound (IVUS) and centrally assessed by the IVUS Core Laboratory. Percent in-stent volume obstruction was calculated as neointimal volume / stent volume \* 100.
Time frame: 6 months
| Milestone | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| Started | 3 | 51 | 3 | 55 |
| Completed | 3 | 49 | 3 | 50 |
| Not completed | 0 | 2 | 0 | 5 |
| Withdrew: Adverse event | 0 | 2 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 |
Toxicities were evaluated based on the U.S. National Cancer Institute (NCI) Common Terminology Criteria (CTC) for Adverse Events version 3.0. Any drug-related toxicities considered CTC Grade 3 or 4 were considered dose limiting. The maximum tolerated dose was defined as the lesser of 45 mg/m\^2 or the dose at which any drug related toxicities were observed.
| participants | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| Phase I: Number of Participants With Dose-limiting Toxicities | 0 | 0 | 0 | 0 |
Procedural complications include the following: 1. Haemodynamic monitoring: changes in heart rate, arterial blood pressure or electrocardiogram changes; 2. Arrhythmia: premature ventricular complexes, brady or tachyarrhythmia; 3. Allergic reactions: rash, flushing, pyrexia, urticaria, angio-oedema; 4. Angiographic complications: coronary artery spasm, dissection, thrombosis, TIMI (Thrombolysis In Myocardial Infarction) flow, no reflow; 5. Clinical changes: chest pain.
| participants | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| Number of Participants With Procedural Complications | 1 | 5 | 1 | 9 |
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. An SAE is any event that: * is fatal or life threatening * results in persistent or significant disability or or incapacity; * requires or prolongs existing hospitalization; * is a congenital anomaly/birth defect in the offspring of a patient who received medication; * conditions not included above that may jeopardize the patient or require intervention to prevent one of the outcomes listed above.
| participants | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| Patients with at Least 1 AE | 3 | 43 | 3 | 48 |
| Patients with at Least 1 Serious AE | 0 | 14 | 0 | 18 |
Binary restenosis was assessed by quantitative coronary angiography and defined as \>50% diameter stenosis within the stented region (In-stent) or the stented region plus 5 mm on either side of the stent (In-segment) at follow-up. Angiograms were centrally assessed by the Angiographic Core Laboratory.
| percentage of participants | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| In-stent | 0.0 | 25.5 | 0.0 | 34.5 |
| In-segment | 0.0 | 27.5 | 0.0 | 34.5 |
Major Adverse Cardiac Events (MACE) includes cardiac death, Coronary Artery Bypass Surgery, Myocardial Infarction, Target Vessel Revascularization (TVR) or Target Lesion Revascularization (TLR) and stent/vessel thrombotic occlusion.
| participants | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| Number of Participants With Major Adverse Cardiac Events (MACE) at 1 Month | 0 | 1 | 0 | 1 |
Major Adverse Cardiac Events (MACE) includes cardiac death, Coronary Artery Bypass Surgery, Myocardial Infarction, Target Vessel Revascularization (TVR) or Target Lesion Revascularization (TLR) and stent/vessel thrombotic occlusion.
| participants | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| Number of Participants With Major Adverse Cardiac Events (MACE) at 6 Months | 0 | 7 | 0 | 16 |
Late lumen loss represents the extent of neointimal hyperplasia within the stented region (In-stent) or the stented region plus 5 mm on either side of the stent (In-segment) and was measured by quantitative coronary angiography. Late Loss = Minimum Lumen Diameter (MLD) Post Procedure minus the MLD at Follow-up.
| mm | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| In-stent [n=3, 46, 3, 50] | 0.403 ± 0.2267 | 0.871 ± 0.4188 | 0.747 ± 0.1626 | 0.835 ± 0.5328 |
| In-segment [n=3, 47, 3, 50] | 0.281 ± 0.2116 | 0.631 ± 0.4070 | 0.355 ± 0.3101 | 0.697 ± 0.5323 |
In-stent volume obstruction at 6 months was measured by intra-vascular ultrasound (IVUS) and centrally assessed by the IVUS Core Laboratory. Percent in-stent volume obstruction was calculated as neointimal volume / stent volume \* 100.
| Percentage of obstruction | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| Percentage of In-Stent Volume Obstruction at 6 Months | 14.080 ± 11.5163 | 24.908 ± 15.3220 | 31.016 ± 8.9722 | 21.663 ± 14.0249 |
Collected over Up to 6 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 mg/m^2 Nanoparticle Paclitaxel | — | 0/3 (0%) | 3/3 (100%) |
| 22 mg/m^2 Nanoparticle Paclitaxel | — | 14/51 (27.5%) | 34/51 (66.7%) |
| 35 mg/m^2 Nanoparticle Paclitaxel | — | 0/3 (0%) | 3/3 (100%) |
| 45 mg/m^2 Nanoparticle Paclitaxel | — | 18/55 (32.7%) | 31/55 (56.4%) |
| Event | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| In-stent coronary artery restenosisInjury, poisoning and procedural complications | 0/3 | 4/51 | 0/3 | 8/55 |
| Coronary artery restenosisInjury, poisoning and procedural complications | 0/3 | 3/51 | 0/3 | 7/55 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 0/3 | 1/51 | 0/3 | 0/55 |
| Myocardial infarctionCardiac disorders | 0/3 | 1/51 | 0/3 | 1/55 |
| Angina pectorisCardiac disorders | 0/3 | 1/51 | 0/3 | 0/55 |
| Chest painGeneral disorders | 0/3 | 1/51 | 0/3 | 1/55 |
| Chest discomfortGeneral disorders | 0/3 | 1/51 | 0/3 | 0/55 |
| Arterial disorderVascular disorders | 0/3 | 1/51 | 0/3 | 0/55 |
| HypertensionVascular disorders | 0/3 | 1/51 | 0/3 | 0/55 |
| Abdominal painGastrointestinal disorders | 0/3 | 1/51 | 0/3 | 0/55 |
| Event | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel |
|---|---|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 2/3 | 4/51 | 1/3 | 3/55 |
| Blood creatine phosphokinase MB increasedInvestigations | 2/3 | 4/51 | 0/3 | 3/55 |
| Troponin T increasedInvestigations | 2/3 | 1/51 | 0/3 | 1/55 |
| DizzinessNervous system disorders | 2/3 | 0/51 | 0/3 | 2/55 |
| Blood creatine phosphokinase increasedInvestigations | 1/3 | 0/51 | 0/3 | 1/55 |
| Electrocardiogram ST-T changeInvestigations | 1/3 | 0/51 | 0/3 | 0/55 |
| White blood cell count decreasedInvestigations | 1/3 | 1/51 | 0/3 | 1/55 |
| Alanine aminotransferase increasedInvestigations | 0/3 | 4/51 | 1/3 | 2/55 |
| Troponin increasedInvestigations | 0/3 | 2/51 | 1/3 | 1/55 |
| Chest discomfortGeneral disorders | 1/3 | 1/51 | 0/3 | 0/55 |
| Age Continuous(years) | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel | Total |
|---|---|---|---|---|---|
| Mean | 63.7 ± 6.51 | 59.0 ± 9.26 | 63.3 ± 6.81 | 60.3 ± 8.89 | 59.9 ± 8.94 |
| Sex: Female, Male(Participants) | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel | Total |
|---|---|---|---|---|---|
| Female | 1 | 20 | 1 | 15 | 37 |
| Male | 2 | 31 | 2 | 40 | 75 |
| Race/Ethnicity, Customized(participants) | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel | Total |
|---|---|---|---|---|---|
| Black, of African Heritage | 0 | 1 | 0 | 3 | 4 |
| White, Non-Hispanic and Non-Latino | 3 | 44 | 3 | 46 | 96 |
| White, Hispanic or Latino | 0 | 6 | 0 | 6 | 12 |
| Weight(kg) | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel | Total |
|---|---|---|---|---|---|
| Mean | 82.80 ± 10.318 | 83.56 ± 13.659 | 91.33 ± 21.333 | 85.01 ± 17.915 | 84.46 ± 15.880 |
| Lesion type(participants) | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel | Total |
|---|---|---|---|---|---|
| Patients with de novo Lesions | 3 | 49 | 3 | 50 | 105 |
| Patients with In-Stent Restenosis Lesions | 0 | 2 | 0 | 5 | 7 |
| Diabetes mellitis(participants) | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel | Total |
|---|---|---|---|---|---|
| No Diabetes | 3 | 40 | 2 | 46 | 91 |
| Insulin Dependent | 0 | 5 | 0 | 1 | 6 |
| Non-Insulin Dependent | 0 | 6 | 1 | 8 | 15 |
| Minimum Lumen Diameter(mm) | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel | Total |
|---|---|---|---|---|---|
| Mean | 0.790 ± 0.3941 | 0.842 ± 0.3628 | 0.762 ± 0.1804 | 0.986 ± 0.3740 | 0.908 ± 0.3691 |
| Reference Diameter(mm) | 10 mg/m^2 Nanoparticle Paclitaxel | 22 mg/m^2 Nanoparticle Paclitaxel | 35 mg/m^2 Nanoparticle Paclitaxel | 45 mg/m^2 Nanoparticle Paclitaxel | Total |
|---|---|---|---|---|---|
| Mean | 2.668 ± 0.0753 | 2.577 ± 0.3899 | 2.650 ± 0.4290 | 2.703 ± 0.4664 | 2.643 ± 0.4259 |
2 further baseline measures are reported on the registry.
No study locations are listed for this record.
The record gives a start of Jul 2005, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumin-Bound Paclitaxel